Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

Apr 20, 06:13 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues an executive order to accelerate FDA reviews of psychedelic therapies, and Lilly’s oral weight loss pill sees strong early prescribing demand.

Share
Subscribe
Next
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive